Abstracts tagged "giant cell arteritis"

Abstract Number: 0698 • ACR Convergence 2024
Association of Systemic Sclerosis with ANCA-Associated Vasculitis and Large Vessel Vasculitis: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder with excessive fibrosis and vasculopathy. While typically non-inflammatory, frank vasculitis can complicate SSc. Concomitant SSc with ANCA-associated…
Abstract Number: 0763 • ACR Convergence 2024
Transcriptional Analysis of Both Normal and Abnormal TABs in Biopsy-proven GCA Reveals a Shared Gene Expression Profile Compared to Clinically Diverse Controls
Ingrid Lindquist¹, Dongseok Choi², Suzanne Fei³, Kiana Vakil-Gilani⁴, Daniela Ghetie¹, David Wilson⁵, Diva Salomao⁶, Hillary Stiefel⁷, Daniel Albert⁷, James Rosenbaum⁸ and Marcia Friedman¹, ¹OHSU, Division of Arthritis and Rheumatic Diseases, Portland, OR, ²OHSU, School of Public Halth, Portland, OR, ³OHSU, Oregon National Primate Research Center, Portland, OR, ⁴OHSU, Division of Arthritis and Rheumatic Diseases, Porltand, OR, ⁵OHSU, Casey Eye Institute, Porrtland, OR, ⁶Mayo Clinic, Division of Anatomic Pathology, Rochester, MN, ⁷OHSU, Casey Eye Institute, Portland, OR, ⁸Corvus Pharmaceuticals and Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over 50 years old and is a clinical diagnosis bolstered by pathologic findings on temporal…
Abstract Number: 1619 • ACR Convergence 2024
Challenges in Managing Polymyalgia Rheumatica and Giant Cell Arteritis: Steroid Dependence and Preventive Care
Vivekanand Tiwari¹, chih fang², Katherine loomba², Nisha Khubchandani², shikha shah² and William Rigby³, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth Hitchcock Medical Center, Lebanon, ³Dartmouth-Hitchcock, Norwich, VT
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…
Abstract Number: 1641 • ACR Convergence 2024
Orbital MRI as a Promising Approach for the Diagnosis of Giant Cell Arteritis in Case of Anterior Ischemic Optical Neuropathy or Central Retinal Artery Occlusion
Guillaume BRENAC¹, Angélique BERNARD¹, Hélène GREIGERT¹, Brivael LEMOGNE², Andre Ramon³, Sylvain AUDIA¹, Vanessa LEGUY-SEGUIN¹, Jérôme RAZANAMAHERY¹, Louis ARNOULD¹, Catherine CREUZOT-GARCHER¹, Bernard Bonnotte⁴ and Maxime SAMSON¹, ¹Dijon University Hospital, Dijon, France, ²Dijon University Hopital, Dijon, France, ³Dijon University Hospital, Besançon, France, ⁴Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France
Background/Purpose: Vision loss associated with acute anterior ischemic optic neuropathy (AION) or central retinal artery occlusion (CRAO) can reveal giant cell arteritis (GCA). In this…
Abstract Number: 0737 • ACR Convergence 2024
Rurality and Delayed Diagnosis of Giant Cell Arteritis – a Single Center Experience
Ruoning (Lemon) Ni¹, Bharat Kumar² and Aleksander Lenert³, ¹Cleveland Clinic, Cleveland, OH, ²University of Iowa Hospitals and Clinics, Iowa City, IA, ³University of Iowa, Iowa City, IA
Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges, especially in rural areas, where limited access to healthcare can delay diagnosis and worsen outcomes, a concern…
Abstract Number: 0764 • ACR Convergence 2024
Primary Treatment Failure to Tocilizumab in Giant Cell Arteritis
Paul Cioni¹, Hubert de Boysson², Simon Parreau³, Perrine SMETS⁴, Maxime SAMSON⁵, Sara Melboucy⁶, Herve Lobbes⁷, Nabil Belfeki⁸, François Perrin⁹, Pascal Maurice Rossi¹⁰, Eric Liozon¹¹, Guillaume Le Guenno¹², Claire Le Jeunne¹, OLIVIER FOGEL¹³, Lola Prat¹⁴, Florent Ladouce¹⁵, Sylvie Grosleron¹⁶, Halil Yildiz¹⁷, Vincent Grosbost¹⁵, Xavier Puéchal¹⁸, Chloe Comarmond¹⁹ and Benjamin Terrier²⁰, ¹Cochin University Hospital, Paris, France, ²Caen university Hospital, Caen, France, ³Dupuytren hospital, Limoges, France, ⁴Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁵Dijon University Hospital, Dijon, France, ⁶CH Saint Quentin, Saint Quentin, France, ⁷CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸GHSIF - Melun, Melun, France, ⁹CH Saint Nazaire, Saint Nazaire, France, ¹⁰CHU Hopital Nord Marseille, Marseille, France, ¹¹CHU Limoges, Limoges, France, ¹²CHU, Clermont-Ferrand, France,, Clermont-Ferrand, France, ¹³AP-HP, Paris, France, ¹⁴Jacques Cartier Hospital, Massy, France, ¹⁵Clermont Ferrand University Hospital, Clermont Ferrand, France, ¹⁶CH Agen-Nerac, Agen, France, ¹⁷Saint-Luc University Clinic, Bruxells, Belgium, ¹⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁹Lariboisière University Hospital, Paris, France, ²⁰Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over the age of 50. Glucocorticoids are the cornerstone of treatment for GCA,…
Abstract Number: 1620 • ACR Convergence 2024
Unveiling of a New Molecular Imaging Biomarker? Vascular Adhesion Protein-1 and [68Ga]Ga-DOTA-Siglec-9 PET/CT in Detecting Giant Cell Arteritis Relapse
Simon Petzinna¹, Jim Küppers², Benedikt Schemmer², Anna Kernder³, Claus Juergen Bauer¹, Pantelis Karakostas¹, Denada Bruci³, Adina Morar³, Anja Winklbauer², Markus Essler² and Valentin S. Schäfer², ¹Clinic of Internal Medicine III, Department of Rheumatology, University Hospital of Bonn, Bonn, Germany, Bonn, Germany, ²University Hospital Bonn, Bonn, Germany, ³University Hospital Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany
Background/Purpose: Vascular adhesion protein-1 (VAP-1) is a transmembrane adhesion molecule with oxidative deamination functionality, which is expressed in vascular smooth muscle cells and endothelial cells.…
Abstract Number: 1695 • ACR Convergence 2024
Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial
Peter Merkel¹, Arathi Setty², Ricardo Blanco-Alonso³, Ravi Suppiah⁴, Thomas Daikeler⁵, Valerie Devauchelle⁶, Elisabeth Brouwer⁷, Hiromichi Tamaki⁸, Liu Meng², Yang Yang², Avani Joshi², Charles Phillips², Peter K. Wung² and Cristina Ponte⁹, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie, North Chicago, IL, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Health New Zealand, Te Toka Tumai Auckland, Auckland, New Zealand, ⁵university hospital, Basel, Switzerland, ⁶UBO, Brest, France, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal
Background/Purpose: Giant cell arteritis (GCA) is a chronic systemic vasculitis with limited targeted therapeutic options. The recent SELECT-GCA phase 3 trial demonstrated a favorable benefit-risk…
Abstract Number: 0738 • ACR Convergence 2024
Quantitative Vascular US Has Additional Diagnostic and Prognostic Value in GCA
Colm Kirby¹, Rachael Flood¹, Sharon Cowley², Emma Finlay³, Ronan Mullan¹, Grainne Murphy⁴ and David Kane⁵, ¹Tallaght University Hospital, DUBLIN, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³School of Biotechnology, Dublin City University, Dublin, Ireland, ⁴Cork University Hospital, Cork, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland
Background/Purpose: Vascular Ultrasound (VUS) performs well in diagnosing Giant Cell Arteritis (GCA) but its role in monitoring disease activity and in predicting outcomes is unknown…
Abstract Number: 0765 • ACR Convergence 2024
Tocilizumab in Extracranial Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
Carmen Lasa Teja¹, Javier Loricera², Diana Prieto-Peña³, fernando lopez gutierrez⁴, Pilar Bernabéu⁵, Mercedes Freire González⁶, ivan Ferraz-Amaro⁷, Santos Castañeda⁸, Mauricio Mínguez⁹, Beatriz bravo-Mancheño¹⁰, Roser Solans-Laqué¹¹ and Ricardo Blanco-Alonso¹², ¹Hospital Universitario Marqués de Valdecilla, Riotuerto, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ⁴Rheumatology, madrid, Madrid, Spain, ⁵Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ⁶Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital San Juan de Alicante, Rheumatology., Alicante, Spain, ¹⁰Hospital Universitario Virgen de las Nieves, Granada, Granada., Spain, ¹¹Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, ¹²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) seems to be effective in large vessel (LV) vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK). LV-GCA phenotype shares some…
Abstract Number: 1622 • ACR Convergence 2024
18F-FDG PET/CT in LVV During Active and Inactive Disease Phases Is Associated with the Metabolic Profile, but Not with Macrophage-related Cytokines: Results of an Integrated Analysis
Dimitrios Anastasios Palamidas¹, Georgios Kalykakis², Dimitra Benaki³, Loukas chatzis¹, Ourania Argyropoulou⁴, Panagiota Palla⁴, Antonia Kollia⁵, Pavlos Kafouris⁵, Marinos Metaxas⁵, Andreas Goules⁶, Emmanuel Mikros⁷, Konstantinos Kambas⁸, Constantinos Anagnostopoulos⁵ and Athanasios Tzioufas⁹, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Department of Informatics, Ionian University, Kerkyra, Greece, Athens, Greece, ³Department of Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁴Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁵PET-CT Department & Preclinical Imaging Unit, Center for Experimental Surgery, Clinical & Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece., Athens, Greece, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁷Department of Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁸Laboratory of Molecular Genetics, Department of Immunology, Hellenic Pasteur Institute, Athens, Greece., Athens, Greece, ⁹LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Giant cell arteritis (GCA) may affect temporal arteries (cranial-GCA) or may present as a systemic disease extended to the large vessels [Large Vessel Vasculitis…
Abstract Number: 1699 • ACR Convergence 2024
Anakinra in Giant Cell Arteritis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Hubert de Boysson¹, Kim Ly², Loik Geffray³, Thomas Quemeneur⁴, Eric Liozon⁵, Holy Bezanahary⁵, Noemie Le Gouellec⁴, Alexandra Audemard⁶, Samuel Deshayes⁷, Jonathan Boutemy⁸, Gwénola Maigné⁸, Nicolas Martin Silva⁸, Jean-Jacques Parienti⁸ and Achille Aouba⁷, ¹Caen university Hospital, Caen, France, ²CHU Limoges, limo, France, ³CH Lisieux, Lisieux, France, ⁴CH Valenciennes, Valenciennes, France, ⁵CHU Limoges, Limoges, France, ⁶Tours, Tours, France, ⁷Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, ⁸CHU Caen, Caen, France
Background/Purpose: A previous retrospective series reported the efficacy and tolerance of anakinra (ANK) in giant cell arteritis (GCA) and called for further validation in a…
Abstract Number: 0742 • ACR Convergence 2024
Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteritis on Tocilizumab
Kaitlin Quinn¹, mark ahlman² and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Radiology and Imaging, Medical College of Georgia, augusta, GA, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: The optimal way to monitor disease activity in patients with GCA on tocilizumab remains uncertain. Acute phase reactants are not a reliable indicator of…
Abstract Number: 0767 • ACR Convergence 2024
Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis
Alison Clifford¹, Jonathan Abele¹, Ryan Hung¹, Paolo Raggi¹, Frank Wuest¹, Jan Andersson¹, Elaine Yacyshyn², Eric Lenza¹, Glen Jickling¹ and Jan Willem Cohen Tervaert¹, ¹University of Alberta, Edmonton, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: 18F-fluoro-deoxyglucose (FDG) is the current standard among radiotracers for PET/CT imaging of large vessel vasculitis (LVV) in giant cell arteritis (GCA), but its performance…
Abstract Number: 1623 • ACR Convergence 2024
Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
Delia Fernández-Lozano¹, Marta Domínguez-Álvaro², Javier Narvaez-García³, Noemí Garrido-Puñal⁴, Eugenio De Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez-Martín¹¹, Itziar Calvo¹², Vicente Aldasoro¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, Patricia Moya¹⁶, María García-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁹Hospital Universitario Donostia, San Sebastián, Spain, ¹⁰Hospital León, LEON, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹²Hospital Universitario de Basurto, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁷Hospital Ramón y Cajal, MADRID, Madrid, Spain, ¹⁸Hospital Universitario de la Princesa, Madrid, Spain, ¹⁹University of Cantabria. IDIVAL, Santander, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a predominantly female vasculitis. There are several studies that attempt to report the differences in the presentation of this…

1
2
3
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].